A 69-year-old retired radio host and disc jockey was referred to the neuro-ophthalmology service for evaluation of a 3-month history of intermittent binocular diplopia and left-sided ptosis.He ...

Key points A 69-year-old man presented to the emergency department with several months of progressive weakness, exertional dyspnea, and recurrent sinopulmonary infections. Over the preceding 6 months, ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis ...

Consensus guidelines from experts appointed by the Myasthenia Gravis Foundation of America (MGFA) indicate thymectomy is an elective procedure and should be performed when a patient is stable and ...

Most generalized MG patients have ocular symptoms at presentation, which progress and cause generalized MG involving the ...

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna. Thursday, the FDA greenlighted ...

Please provide your email address to receive an email when new articles are posted on . FDA approves inebilizumab-cdon for adults with anti-acetylcholine receptor and anti-muscle specific tyrosine ...

In the overall population, inebilizumab demonstrated a statistically significant improvement in MG-ADL total score compared with placebo. The Food and Drug Administration (FDA) has approved Uplizna ® ...

MG Lexicon will help patients and medical professionals communicate and share common information concerning the rare autoimmune, neuromuscular disease myasthenia gravis BOSTON, Dec. 5, 2025 ...

Objective: To present an atypical case of recurrent thoracic thymoma in the thorax with secondary spinal invasion and to review the role of surgical intervention in the treatment of the disease based ...